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identiﬁed as Lgr5-positive cells (Flesken-Nikitin et al., 2013; Ng et al.,
2014), and Lgr5-positive epithelial stem cells are prone for genetically
engineered ovarian cancer. Since Lgr5 is induced byWnt/β-Catenin sig-
naling, Wnt/β-Catenin signaling in epithelial stem cells seems to be ac-
tivated (Barker et al., 2013). SOX2 is also induced by Wnt/β-Catenin
signaling, indicating that epithelial stem cells that are sensitive for ovar-High-grade serous ovarian cancer (HGSOC) has a highmortality rate
because the disease is asymptomatic in early stages and is resistant to
treatments. A novelmodality for diagnosis in the early stages of carcino-
genesis is needed. In this issue of EBioMedicine, Hellner et al. present
novel genetic aspects of small lesions of HGSOC (Hellner et al., 2016).
They performed screening by LFRWGS technology for small HGSOC le-
sions from a patient who underwent treatment and found 750 genomic
mutations. Gene ontology analysis revealed that the genemutations are
related to stem cell differentiation, and the authors ﬁnally found 6 novel
non-codingmutations (BB1 - BB6) in proximity of sex determining region
Y-box2 (SOX2), a key driver of stem cell differentiation (Takahashi and
Yamanaka, 2006). Deep genetic analysis revealed that the BB5 region
is commonly mutated in HGSOC tissues. A reporter assay and genome
engineering using CRISPR/Cas9 system revealed that the BB5 region is
a novel repressor of the SOX2 gene and that mutation in the BB5 region
induces protein expression of SOX2. Mutations in the BB5 region were
detected in non-neoplastic fallopian tube epithelium (FTE) of HGSOC
cases and also in normal FTE of BRCA1 or BRCA2mutation carriers who
are at high risk for HGSOC. Surprisingly, immunohistochemical analysis
of BB5 mutation carriers revealed that SOX2 protein is broadly
expressed in even normal FTEs, indicating that non-neoplastic FTEs
with BB5 mutation propagated clonally. SOX2 protein is expressed in
earlier stages than TP53 protein expression indicating overexpression
of SOX2 protein is earlier event than TP53 gene mutation. Interestingly,
SOX2 protein expression decreased after the establishment of an ovari-
an cancer lesion. These results suggest thatmutation in the SOX2 BB5 re-
gion is an early carcinogenesis driver mutation in HGSOCs and that
detection of SOX2 protein is a promising biological marker for predic-
tion of HGSOC.om.2016.06.048.
i), torigoe@sapmed.ac.jp
en access article under the CC BY-NCIn mouse models, stem cells in the ovary and tubal epithelia were
ian carcinogenesis are positive for SOX2. However, a recent study re-
vealed that SOX2 protein is induced by mechanisms other than
activation of Wnt/β-Catenin signaling (Hellner et al., 2016).
SOX2 protein expression was found to be decreased in HGSOC tis-
sues in this study. On the other hand, SOX2 is overexpressed in ovarian
cancer stem cells (CSCs) (Bareiss et al., 2013; Mariya et al., 2016), and
SOX2 expression is essential for tumorigenicity of ovarian CSCs. There-
fore, detection of SOX2 protein in vivo is important not only for early de-
tection of high-risk FTEs but also for prediction of the outcome in
advanced HGSOC cases. Finally, SOX2 protein might have two function-
al roles in the development of HGSOCs: (I) SOX2 protein is expressed in
normal FTEs with BB5mutation and may have a role in clonal propaga-
tion in situ, and SOX2-positive FTEs are prone for HGSOCs and (II) after
generation of an HGSOC lesion, SOX2 protein is expressed in a small
subpopulation of HGSOC cancer stem cells. SOX2 is a transcription fac-
tor and further analysis of SOX2 target genes both in normal FTEs and
cancer stem cells reveal the different functions of SOX2 protein in
both cells.
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